Investor Education Webinar
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders...
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 key results 1 Group performance 2...
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px...
Telix Full Year Results 2025 Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026...
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the...
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4...
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has...
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate...
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual...
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: TLX591-CDx (Illuccix® in approved jurisdictions,...